A Research Guide for
Restless Legs Syndrome

Iron is essential for the normal function of dopamine-producing neurons. It is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Brain iron deficiency — which can exist even when blood iron levels appear adequate — leads to reduced dopamine production and altered dopamine receptor function in the basal ganglia and other motor circuits.

Autopsy and MRI studies consistently show reduced brain iron in RLS patients, particularly in the substantia nigra. Cerebrospinal fluid studies show low ferritin and high transferrin, indicating that the brain is iron-deficient even when peripheral blood markers look normal. This is why the ferritin threshold for RLS treatment is set at 75 ng/mL — considerably higher than the general “normal” range of 12–30 ng/mL that most labs report.

Dopamine signaling in the brain follows a circadian rhythm, with lower dopaminergic activity in the evening and at night. In people with RLS, the combination of underlying iron-related dopamine dysfunction and the normal evening dip in dopaminergic tone tips the system below a threshold — and symptoms emerge. This explains the characteristic worsening of RLS in the evening and at night.

It also explains why dopamine agonist medications help in the short term: they stimulate dopamine receptors directly. However, chronic dopaminergic stimulation can lead to receptor downregulation and sensitization — and this is the mechanism underlying augmentation, the most important complication of dopamine agonist therapy (discussed in detail in the Active Management section).

While the iron-dopamine axis is central, other systems contribute. Glutamate, the brain’s primary excitatory neurotransmitter, appears to be elevated in the thalamus of RLS patients, contributing to the hyperarousal and sensory discomfort. The endogenous opioid system is also involved — opioid receptor binding is altered in RLS, which helps explain why low-dose opioids are effective in refractory cases and why the adenosine system (linked to dipyridamole research) is being explored. GABA signaling may also be altered, which provides one rationale for the efficacy of alpha-2-delta ligands like gabapentin and pregabalin.

Primary RLS has no identifiable external cause. It tends to run in families, begins earlier in life (often before age 40–45), and follows a slowly progressive course. The underlying mechanism involves genetically mediated alterations in brain iron handling and dopaminergic function. Primary RLS is a lifelong condition, though its severity can fluctuate. It typically requires long-term management.

Secondary RLS occurs in the context of another medical condition or medication. Treating the underlying cause may substantially improve or completely resolve RLS symptoms. The most important secondary causes include:

• Iron deficiency — the most common and most treatable secondary cause. Any condition causing iron depletion (heavy menstruation, GI blood loss, frequent blood donation, celiac disease) can trigger or worsen RLS.
• End-stage renal disease (ESRD) / chronic kidney disease — RLS affects 20–60% of dialysis patients. Iron deficiency is common in this population, and uremia itself may impair dopaminergic function.
• Pregnancy — RLS affects roughly one-quarter of pregnant women, especially in the third trimester. It typically resolves within weeks of delivery. Iron and folate deficiency during pregnancy are contributing factors.
• Peripheral neuropathy — neuropathy from diabetes, vitamin deficiencies, or other causes can trigger RLS-like symptoms or coexist with primary RLS.
• Medications — many common drugs can cause or worsen RLS (detailed in the Active Management section).

Roughly 80–90% of people with RLS also have PLMS when monitored by polysomnography (sleep study). However, PLMS are also common in older adults without RLS and can occur with other sleep disorders or as a side effect of medications. PLMS without RLS symptoms may not require treatment.

When PLMS are severe enough to fragment sleep and cause daytime impairment, and RLS is not present, the condition is called Periodic Limb Movement Disorder (PLMD). PLMD is a separate diagnosis that may warrant treatment in its own right.

The clinical significance of PLMS in patients with RLS is debated. Some specialists use PLMS counts (measured as the Periodic Limb Movement Index, or PLMI) as an objective marker of RLS severity or treatment response, while others focus primarily on patient-reported symptoms.

When evaluating any RLS treatment claim, ask these questions:

• Has it been tested in a peer-reviewed clinical trial in patients with diagnosed RLS?
• Is the evidence from a randomized, controlled study, or just testimonials and anecdotes?
• Do sleep medicine specialists at academic centers recommend it?
• Could it interfere with your current RLS medications?
• Does anyone selling it have a financial interest in the claim?

Be especially cautious of supplements claiming to “cure” RLS, devices marketed directly to consumers without FDA clearance, and anyone who suggests you stop your prescribed medications. While iron supplementation and lifestyle changes have real evidence, most over-the-counter “restless legs” products do not.

All five of the following must be present for a diagnosis of RLS:

1. An urge to move the legs, usually accompanied by or in response to uncomfortable and unpleasant sensations in the legs. (In some cases, the urge to move may be present without uncomfortable sensations, and arms or other body parts may also be affected.)
2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying down or sitting.
3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
4. The urge to move or unpleasant sensations occur exclusively or predominantly in the evening or night. (In severe, long-standing cases, the worsening at night may not be noticeable but must have been present at some point in the course of the condition.)
5. The symptoms are not solely accounted for by another medical or behavioral condition (e.g., leg cramps, positional discomfort, arthritis, leg edema, habitual foot tapping).

Once diagnosed, RLS severity is typically assessed using the International RLS Rating Scale (IRLS), a validated 10-question questionnaire that scores from 0 to 40:

• Mild: 1–10
• Moderate: 11–20
• Severe: 21–30
• Very severe: 31–40

Treatment decisions are generally guided by severity, frequency of symptoms, and impact on sleep and quality of life. Mild, intermittent RLS may be managed with lifestyle measures and iron optimization alone. Moderate-to-severe RLS typically warrants pharmacological treatment.

• Serum ferritin — the single most important lab test in RLS. A fasting, morning ferritin level should be obtained. The RLS-specific threshold is 75 ng/mL. Values below this warrant iron supplementation, even if they fall within the laboratory’s general “normal” range. Ferritin is an acute-phase reactant and can be falsely elevated by inflammation — if CRP is elevated, the ferritin may not reflect true iron stores.
• Transferrin saturation (TSAT) — values below 20% suggest functional iron deficiency. Should be checked alongside ferritin.
• Complete blood count (CBC) — to identify anemia or other hematologic abnormalities.
• Comprehensive metabolic panel — to screen for kidney disease (elevated creatinine, low GFR), which is a major secondary cause.
• Thyroid function (TSH) — thyroid disease can mimic or worsen RLS.
• Hemoglobin A1c or fasting glucose — to screen for diabetes, which can cause neuropathy-related RLS.
• Vitamin B12 and folate — deficiencies can cause neuropathy and contribute to RLS.
• Magnesium — low magnesium can cause leg cramps and may contribute to RLS symptoms.

A polysomnogram (overnight sleep study) is not required to diagnose RLS. However, it may be useful in the following situations:

• When the diagnosis is uncertain and objective documentation of periodic limb movements would be helpful
• When a concurrent sleep disorder (especially obstructive sleep apnea) is suspected
• When daytime sleepiness is out of proportion to the reported sleep disruption from RLS
• When PLMD (periodic limb movement disorder without RLS) is being considered as a separate diagnosis
• When treatment response is poor and objective measurement is needed

The polysomnogram measures the Periodic Limb Movement Index (PLMI) — the number of periodic limb movements per hour of sleep. A PLMI greater than 15 per hour in adults is considered elevated.

The SIT is a clinical test sometimes used in research settings. The patient sits reclined in bed for 60 minutes in the evening without moving their legs, and leg movements and discomfort are recorded. It can help distinguish RLS from mimics and can objectively quantify symptom severity. It is not widely used in routine clinical practice but may be available at sleep medicine centers.

• Nocturnal leg cramps — sudden, painful muscle contractions (charley horses). Unlike RLS, cramps cause visible muscle tightening and acute pain, not an urge to move. They resolve with stretching the muscle, not general movement.
• Positional discomfort — numbness or tingling from crossing legs or awkward postures. Resolves with repositioning, not specific to evening/night, not an urge to move.
• Peripheral neuropathy — burning, tingling, or numbness in the feet and legs from nerve damage (commonly diabetic). The discomfort is constant, not specifically rest-triggered or relieved by movement, and may worsen at night but does not have the circadian pattern of RLS. Some patients have both conditions.
• Venous insufficiency / varicose veins — aching, heaviness, and restlessness in the legs that worsens with standing and improves with elevation. Differs from RLS in timing pattern.
• Akathisia — inner restlessness and inability to sit still, typically caused by antipsychotic or anti-emetic medications. Involves the whole body, is not circadian, and is not specifically relieved by movement.
• Anxiety and psychomotor agitation — generalized restlessness that is not localized to the legs and lacks the specific circadian and movement-relief pattern of RLS.
• “Growing pains” in children — some children diagnosed with growing pains actually have RLS, especially if symptoms are specifically in the evening and legs, with family history.

• ☐ Confirm diagnosis meets all five IRLSSG criteria
• ☐ Fasting morning ferritin and transferrin saturation drawn
• ☐ CBC, CMP, TSH, HbA1c, B12, folate, magnesium checked
• ☐ Complete medication review for drugs that worsen RLS (antihistamines, SSRIs/SNRIs, anti-nausea drugs, antipsychotics)
• ☐ Screen for secondary causes: iron deficiency, kidney disease, neuropathy, pregnancy
• ☐ If ferritin is below 75 ng/mL: begin iron supplementation (oral or consider IV if <30 or poor oral tolerance)
• ☐ Assess severity using IRLS rating scale
• ☐ Discuss and initiate lifestyle modifications (exercise timing, sleep hygiene, caffeine/alcohol reduction)
• ☐ If pharmacotherapy needed: discuss alpha-2-delta ligands as preferred first-line
• ☐ If already on a dopamine agonist: assess for augmentation
• ☐ Consider referral to sleep medicine specialist for moderate-to-severe or complex cases
• ☐ Family history documented (first-degree relatives with RLS)

For patients with ferritin between 30–75 ng/mL:

• Ferrous sulfate 325 mg (65 mg elemental iron) taken every other day on an empty stomach with vitamin C (200 mg) to enhance absorption.
• Every-other-day dosing is now preferred over daily dosing based on iron absorption studies showing that daily dosing triggers hepcidin elevation, which paradoxically reduces absorption the next day.
• Avoid taking iron with calcium, antacids, coffee, tea, or dairy, which impair absorption.
• Recheck ferritin after 3 months. The goal is ferritin above 75 ng/mL, ideally above 100 ng/mL.
• Common side effects include constipation, nausea, and dark stools. If ferrous sulfate is not tolerated, ferrous bisglycinate (iron bisglycinate) is a gentler alternative with reasonable absorption.

Caregiver note: Iron supplementation requires patience. Symptom improvement may take 6–12 weeks to become apparent even when ferritin is rising appropriately. Stay the course and recheck levels on schedule.

IV iron is appropriate when:

• Ferritin is below 30 ng/mL (moderate-to-severe iron deficiency)
• Oral iron is not tolerated or has failed to raise ferritin after 3 months
• Rapid repletion is needed for severe symptoms
• Iron absorption is impaired (celiac disease, inflammatory bowel disease, gastric bypass)

Common IV iron formulations include ferric carboxymaltose (Injectafer), iron sucrose, and low-molecular-weight iron dextran. Ferric carboxymaltose can deliver a large dose (750–1000 mg) in a single infusion, which is convenient.

Multiple randomized controlled trials have demonstrated that IV iron improves RLS symptoms. The evidence is strongest for ferric carboxymaltose, which has shown sustained improvement in IRLS scores in placebo-controlled trials.

• What is my fasting ferritin level, and is it above 75?
• What is my transferrin saturation?
• Do I have any reason for ongoing iron loss that should be investigated (GI bleeding, heavy periods)?
• Should I try oral iron first, or do I qualify for IV iron?
• How long should I take iron before we reassess?
• Are there reasons to investigate why my iron is low (celiac disease, other causes)?

Alpha-2-delta calcium channel ligands are now recommended as the preferred initial pharmacotherapy for RLS by the IRLSSG, AASM, and most expert consensus guidelines. They carry no risk of augmentation, which gives them a fundamental advantage over dopamine agonists.

• Gabapentin enacarbil (Horizant) — the only alpha-2-delta ligand with a specific FDA indication for moderate-to-severe primary RLS. Dosed at 600 mg once daily, taken at approximately 5 PM with food. This is a sustained-release prodrug of gabapentin that provides more consistent blood levels than standard gabapentin. It was approved based on two large phase 3 trials (NCT00298623 and NCT00365352) showing significant improvement in IRLS scores versus placebo.
• Pregabalin (Lyrica) — used off-label for RLS at doses of 75–300 mg taken 1–2 hours before bedtime. A key study by Allen et al. (2014) compared pregabalin to pramipexole and placebo and found pregabalin equally effective for RLS symptoms, with better sleep quality outcomes and no augmentation risk at one year. Pregabalin is a Schedule V controlled substance due to potential for misuse.
• Gabapentin (Neurontin) — used off-label for RLS at doses of 300–900 mg taken in the evening. Less well-studied than gabapentin enacarbil or pregabalin for RLS specifically, and its absorption is nonlinear (less consistent at higher doses), but it is widely used and substantially cheaper. Often tried first due to cost and familiarity.

Side effects: Drowsiness, dizziness, weight gain, and peripheral edema. These are usually dose-dependent and often improve over time. Starting at a low dose and titrating up helps minimize initial side effects.

Dopamine agonists were historically first-line for RLS but are now recommended as second-line due to the risk of augmentation. They remain effective and appropriate for patients who do not respond to or cannot tolerate alpha-2-delta ligands.

• Pramipexole (Mirapex) — taken orally, 0.125–0.5 mg, 2–3 hours before symptom onset. FDA-approved for RLS.
• Ropinirole (Requip) — taken orally, 0.25–4 mg, 1–3 hours before symptom onset. FDA-approved for RLS.
• Rotigotine transdermal patch (Neupro) — applied daily, 1–3 mg/24h. FDA-approved for RLS. The patch provides continuous 24-hour dopaminergic stimulation, which may reduce (but does not eliminate) augmentation risk and is useful for patients with daytime symptoms.

Side effects beyond augmentation: Nausea, headache, dizziness, nasal congestion. A rare but serious side effect is impulse control disorder (ICD) — compulsive gambling, shopping, eating, or sexual behavior. Patients and family members should be warned about this and report any behavioral changes promptly. ICDs may affect 6–17% of patients on dopamine agonists and resolve after the medication is stopped.

Clonazepam (Klonopin) was historically used for RLS but is no longer recommended as a primary treatment. It may reduce periodic limb movements and improve sleep continuity but does not directly address the urge to move or the uncomfortable sensations. It carries risks of daytime sedation, cognitive impairment, falls (especially in elderly patients), dependence, and tolerance. It may have a limited role as a short-term adjunct in specific situations, but this should be discussed carefully with the treating physician.

Augmentation develops gradually and can be difficult to recognize because it looks like worsening RLS. The key features that distinguish augmentation from natural disease progression are:

• Earlier onset of symptoms: Symptoms that used to begin at 9 PM now start at 5 PM or even in the afternoon.
• Faster onset at rest: Symptoms that used to take 30 minutes of sitting to develop now appear within minutes.
• Spread to other body parts: Symptoms that were confined to the lower legs now affect the thighs, arms, or trunk.
• Greater overall intensity: Symptoms are more intense than they were before treatment began.
• Shorter duration of relief from medication: The medication seems to wear off faster, or the dose that used to work all evening now only lasts a few hours.

Augmentation rates vary by study and definition, but long-term data are sobering:

• With pramipexole: augmentation rates of 30–70% have been reported over 5–10 years of treatment.
• With ropinirole: similar rates to pramipexole.
• With rotigotine patch: lower rates reported (possibly due to continuous dopaminergic stimulation), but augmentation still occurs.
• With levodopa: highest rates — roughly 60–80% within 1–2 years. Levodopa is no longer recommended for daily RLS treatment for this reason.
• With alpha-2-delta ligands (gabapentin enacarbil, pregabalin): essentially zero augmentation risk, which is the primary reason these are now preferred first-line.

Risk factors for augmentation include higher dopamine agonist doses, longer duration of treatment, lower ferritin levels, family history of RLS, and more severe baseline symptoms.

Managing augmentation requires a deliberate, staged approach, ideally guided by a sleep medicine specialist experienced with this problem:

1. Confirm the diagnosis. Verify that the worsening is augmentation and not natural progression, iron deficiency, or medication interaction. Check ferritin — augmentation is more likely and more severe when iron stores are low.
2. Optimize iron. Regardless of other changes, ensure ferritin is above 75 ng/mL, ideally above 100 ng/mL. IV iron may be needed.
3. If augmentation is mild: Reduce the dopamine agonist to the lowest effective dose. Split the dose (adding an afternoon dose rather than increasing the evening dose). Add an alpha-2-delta ligand as an adjunct.
4. If augmentation is moderate-to-severe: Gradually taper and discontinue the dopamine agonist entirely. Bridge with an alpha-2-delta ligand and, in severe cases, a low-dose opioid during the withdrawal period.

• Am I on a dopamine agonist, and if so, at what dose? Is it the lowest effective dose?
• My symptoms seem worse than before — could this be augmentation rather than worsening disease?
• What is my current ferritin level?
• Should we consider switching from a dopamine agonist to an alpha-2-delta ligand?
• If we need to taper the dopamine agonist, what is the plan for managing the withdrawal period?
• Would you refer me to a sleep medicine specialist who has experience managing augmentation?

Low-dose opioid therapy is an established treatment for severe, refractory RLS. It is supported by a randomized controlled trial and by expert consensus guidelines. The evidence and clinical experience support:

• Extended-release oxycodone/naloxone (Targinact/Targin) — the most well-studied opioid for RLS. A pivotal randomized, double-blind, placebo-controlled trial (NCT01112644) showed significant improvement in IRLS scores and sleep quality in patients with severe RLS refractory to other treatments. The naloxone component reduces constipation. This formulation is available in Europe and some other markets but is not available in the United States.
• Low-dose oxycodone, methadone, or tramadol — used in the US for refractory RLS. Methadone at very low doses (5–20 mg daily) has the longest track record and published case series showing sustained efficacy without augmentation. Tramadol is a weaker option sometimes tried first.

Opioid therapy for RLS carries real risks: dependence, tolerance, constipation, drowsiness, and respiratory depression. These risks must be weighed against the significant morbidity of untreated severe RLS, including chronic sleep deprivation, depression, and suicidal ideation. When opioids are used for RLS, doses are typically much lower than those used for chronic pain, and the prescribing should be managed by a specialist experienced with this approach.

For patients with severe or refractory RLS, combination therapy — using medications from different drug classes together — may be more effective than monotherapy. Common combinations include:

• Alpha-2-delta ligand (pregabalin or gabapentin enacarbil) + low-dose dopamine agonist
• Alpha-2-delta ligand + low-dose opioid
• Low-dose dopamine agonist + low-dose opioid (for severe cases resistant to other approaches)

The principle of combination therapy is that lower doses of each drug can be used, reducing side effects while covering different aspects of the symptom profile. This approach should be guided by a specialist.

Iron deficiency, even in the absence of anemia, is the most common treatable cause of RLS. Sources of iron loss that should be investigated include heavy menstrual bleeding, gastrointestinal blood loss (ulcers, colon polyps, inflammatory bowel disease), frequent blood donation, celiac disease, and other malabsorption conditions. Bariatric surgery patients are at particular risk due to reduced iron absorption.

RLS affects 20–60% of patients on hemodialysis and is one of the most common complaints in this population. The mechanism involves both iron deficiency (dialysis patients are frequently iron-depleted) and uremic effects on dopaminergic function. Treatment includes aggressive iron repletion (IV iron is standard in dialysis patients), alpha-2-delta ligands (dose-adjusted for renal function), and in some cases low-dose dopamine agonists. Kidney transplantation often substantially improves or resolves RLS.

RLS affects roughly one-quarter of pregnant women, with symptoms peaking in the third trimester and typically resolving within weeks of delivery. Iron and folate deficiency during pregnancy are major contributing factors. Treatment during pregnancy is primarily iron supplementation and lifestyle measures, as most RLS medications are not established as safe during pregnancy. Pneumatic compression devices may provide relief without medication. Patients who develop RLS during pregnancy have an increased risk of developing chronic RLS later in life.

Small-fiber neuropathy, particularly from diabetes, can produce symptoms that overlap with or trigger RLS. When neuropathy and RLS coexist, treating the neuropathy (optimizing glucose control, addressing vitamin deficiencies) may improve both conditions. Alpha-2-delta ligands (gabapentin, pregabalin) are particularly useful in this setting because they treat both conditions simultaneously.

A careful medication review is essential for every RLS patient. The following drug classes are known to cause or significantly worsen RLS:

• Antihistamines (diphenhydramine/Benadryl, hydroxyzine, many OTC sleep aids) — among the most common culprits. Patients with RLS should avoid all first-generation antihistamines.
• SSRIs and SNRIs (sertraline, fluoxetine, paroxetine, venlafaxine, duloxetine) — most antidepressants in these classes worsen RLS. Bupropion (Wellbutrin) and trazodone are generally better tolerated and may be substituted when an antidepressant is needed.
• Dopamine-blocking anti-emetics (metoclopramide/Reglan, prochlorperazine/Compazine) — can dramatically worsen RLS. Ondansetron (Zofran) is a safe alternative for nausea.
• Antipsychotic medications (both typical and atypical) — block dopamine receptors. If an antipsychotic is medically necessary, quetiapine at low doses may be the least problematic.
• Lithium — may worsen RLS in some patients.

Regular moderate exercise has been shown to reduce RLS symptom severity in several studies. However, exercise timing is important — vigorous exercise too close to bedtime can temporarily worsen symptoms. General guidelines:

• Aim for 30–60 minutes of moderate aerobic exercise (walking, cycling, swimming) most days.
• Complete vigorous exercise at least 4–6 hours before bedtime.
• Gentle stretching or yoga in the evening may be helpful.
• Avoid prolonged immobility during the day — take walking breaks during sedentary work.

Good sleep hygiene does not treat the underlying RLS, but it creates conditions that make it easier to fall and stay asleep once symptoms are managed:

• Maintain a consistent sleep-wake schedule, even on weekends.
• Keep the bedroom cool, dark, and quiet.
• Avoid screens (blue light) for 30–60 minutes before bed.
• Use the bed only for sleep and intimacy — not for watching TV, working, or reading for extended periods.
• If RLS prevents sleep for more than 20–30 minutes, get up and do a quiet activity until symptoms subside, then return to bed.

• Iron-rich foods: Red meat, dark-meat poultry, shellfish (oysters, clams), lentils, beans, spinach, fortified cereals. Pair plant-based iron sources with vitamin C (citrus, bell peppers) to enhance absorption.
• Caffeine: Reduce or eliminate caffeine, especially after noon. Caffeine is an adenosine receptor antagonist that may worsen RLS. Sources include coffee, tea, cola, chocolate, and energy drinks.
• Alcohol: Reduce or eliminate alcohol, especially in the evening. Alcohol disrupts sleep architecture and can worsen RLS symptoms.
• Tobacco: Nicotine is a stimulant that may worsen RLS. Smoking cessation is recommended for general health and may improve symptoms.

• Leg massage and stretching: Many patients find relief from massaging or stretching the legs when symptoms arise.
• Hot or cold applications: A warm bath before bed, or alternating hot and cold packs on the legs, may provide temporary relief. Individual responses vary — experiment to find what works.
• Counter-stimulation: Some patients find that rubbing the legs with a textured surface or wearing compression stockings helps.
• Mental distraction: Engaging in a mentally absorbing activity (puzzles, games, reading) can reduce awareness of symptoms, though it does not treat the underlying cause.
• Pneumatic compression devices: Sequential pneumatic compression (similar to devices used for blood clot prevention) has shown benefit in small studies and is FDA-cleared for RLS (the Restiffic foot wrap and similar devices). Evidence is limited but the approach is low-risk.

Caregiver note: Partners of RLS patients are often affected by the patient’s leg movements at night. Separate sleeping arrangements during severe episodes are practical, not a sign of relational problems. Address this openly — both partners need adequate sleep.

Dipyridamole, a medication traditionally used as an antiplatelet agent, has emerged as a promising investigational treatment for RLS through its effects on adenosine signaling. Adenosine is a neuromodulator that interacts with the dopaminergic system, and preclinical evidence suggests that enhancing adenosine signaling may address the underlying neural circuitry dysfunction in RLS.

A randomized, double-blind, placebo-controlled proof-of-concept study of dipyridamole in RLS showed improvement in IRLS scores (verify current trials on ClinicalTrials.gov), and further research is ongoing. Dipyridamole is already an FDA-approved medication (for other indications), which would simplify its path to clinical use if efficacy is confirmed. Side effects include headache, dizziness, and GI upset.

EMERGING — Promising early data, further trials needed.

Anecdotal reports and survey data suggest that some RLS patients find symptom relief from cannabis products. However, rigorous clinical trial evidence is essentially lacking. A few small observational studies and case series have reported improvement in RLS symptoms with inhaled or oral cannabis, but no adequately powered, randomized, placebo-controlled trial has been published.

The legal status of cannabis varies widely by jurisdiction. The endocannabinoid system does interact with dopaminergic, glutamatergic, and opioid pathways in ways that are theoretically relevant to RLS, but the clinical evidence base does not currently support routine recommendation. Patients who choose to explore cannabis for RLS should do so with their physician’s knowledge and should understand that quality, dosing, and product composition are highly variable.

EMERGING — Anecdotal interest, insufficient trial evidence.

Neuroimaging studies have shown elevated glutamate levels in the thalamus of RLS patients, suggesting that glutamatergic hyperexcitability may contribute to sensory symptoms. This has prompted interest in glutamate-modulating agents, including perampanel (an AMPA receptor antagonist approved for epilepsy) and other compounds. Early-phase studies are exploring whether targeting glutamate signaling can provide relief, particularly for the sensory component of RLS that is not fully addressed by dopaminergic or GABAergic medications.

EMERGING — Biologically plausible, early-stage research.

The identification of MEIS1 as the strongest genetic risk locus for RLS has opened research into targeted interventions. MEIS1 is a transcription factor involved in iron regulation and neuronal development. Research is exploring whether modulating the MEIS1 pathway or its downstream effects could provide disease-modifying treatment. This work is still in preclinical stages but represents a potential shift from symptomatic treatment to addressing root causes.

PRECLINICAL — Basic science research, not yet in clinical trials.

One peripheral neurostimulation device is now FDA-cleared for RLS; the others remain investigational:

• Tonic Motor Activation (TOMAC) — Noctrix Nidra / NTX100: a non-invasive device worn on the legs that delivers high-frequency electrical stimulation over the peroneal nerve. It received FDA De Novo authorization in April 2023 for moderate-to-severe medication-refractory RLS, and the 2024 AASM clinical practice guideline gives it a conditional recommendation. This is the one FDA-cleared neurostimulation option for RLS — useful for patients who cannot tolerate or wish to avoid medication.
• Transcranial direct current stimulation (tDCS) — non-invasive brain stimulation applied to the motor cortex. Small studies have shown short-term improvement in RLS symptoms. Larger trials are needed.
• Repetitive transcranial magnetic stimulation (rTMS) — similar preliminary positive results in small studies.
• Spinal cord stimulation — case reports and small series in severe, refractory RLS have shown benefit, but this is an invasive procedure reserved for extreme cases and is not an established treatment.

FDA-CLEARED TOMAC/Nidra  ·  EMERGING tDCS, rTMS, and spinal cord stimulation remain early-stage and not ready for routine clinical use.

• Levodopa/carbidopa as daily long-term therapy DE-ADOPTED
  Levodopa was one of the first dopaminergic treatments used for RLS and initially showed efficacy. However, augmentation rates of 60–80% within 1–2 years made daily long-term use untenable. It is no longer recommended for ongoing RLS management. Occasional intermittent use (e.g., for a long flight) may still be considered by some specialists.
• Clonazepam as primary RLS therapy DE-ADOPTED
  Clonazepam was widely prescribed for RLS in the 1980s–1990s but does not address the core sensory symptoms and carries significant risks of dependence, cognitive impairment, and falls. It has been supplanted by more targeted therapies and is no longer recommended as a primary treatment.
• Cabergoline WITHDRAWN
  This long-acting dopamine agonist showed efficacy for RLS but was withdrawn from RLS treatment due to the risk of cardiac valvulopathy (fibrotic heart valve disease) with prolonged use. It should not be used for RLS.
• High-dose dopamine agonist monotherapy FAILED
  The historical approach of titrating dopamine agonist doses upward to chase worsening symptoms has been recognized as counterproductive — higher doses accelerate augmentation. The current standard is to use the lowest effective dose and to switch drug classes rather than escalate.

FDA-approved medications specifically indicated for RLS include: gabapentin enacarbil (Horizant), pramipexole (Mirapex), ropinirole (Requip), and rotigotine transdermal patch (Neupro). Pregabalin and gabapentin are widely used off-label. Extended-release oxycodone/naloxone (Targinact) is not available in the US; refractory cases are treated with other opioid formulations off-label.

The EMA has approved ropinirole, pramipexole, and rotigotine for RLS. Extended-release oxycodone/naloxone (Targinact/Targin) is approved in several European countries for severe RLS refractory to dopaminergic therapy — a treatment option not available in the US. Pregabalin is increasingly used off-label following published evidence. The EURLSSG/IRLSSG joint guidelines are widely followed across Europe.

Pramipexole is approved for RLS in Japan. The rotigotine patch is also available. RLS awareness has been growing in Japan, where prevalence is lower than in Western populations but the condition is increasingly recognized and treated by sleep medicine specialists.

Pramipexole, ropinirole, and rotigotine are approved for RLS in Canada. Gabapentin enacarbil (Horizant) is not available in Canada; standard gabapentin and pregabalin are used off-label. In Australia, similar approvals exist. Both countries follow guidelines that closely align with IRLSSG/AASM recommendations. Access to off-label treatments may require specialist prescription and may not be subsidized by public insurance.

• Oxycodone/naloxone (Targinact): Available in Europe for refractory RLS; not available in the US.
• Gabapentin enacarbil (Horizant): Available in the US and Japan; not available in many other countries.
• IV iron access: Availability and insurance coverage for IV iron infusions varies widely. In the US, insurance authorization may require documentation of failed oral therapy.

• Do my symptoms meet the diagnostic criteria for RLS?
• What is my fasting ferritin level, and is it above 75 ng/mL?
• What is my transferrin saturation?
• Are any of my current medications known to worsen RLS?
• Should I be tested for kidney disease, diabetes, or thyroid problems?
• Do I need a sleep study, or can we diagnose this clinically?
• Is there a family history pattern that suggests primary (genetic) RLS?

• Should we start with iron supplementation, and oral or IV?
• If I need medication, would you recommend an alpha-2-delta ligand (gabapentin enacarbil, pregabalin) or a dopamine agonist — and why?
• If you are recommending a dopamine agonist, what is the augmentation risk, and how will we monitor for it?
• What are the side effects I should watch for?
• What lifestyle changes should I make alongside medication?
• How will we measure whether treatment is working?

• My symptoms are getting worse — could this be augmentation?
• Are my symptoms starting earlier in the day than when I began treatment?
• Have my symptoms spread to my arms or other body parts?
• What is the plan if this is augmentation — should we taper the dopamine agonist?
• Should I see a sleep medicine specialist who has experience managing augmentation?
• What medications can help during the transition period?

• I have tried multiple medications without adequate relief. What options remain?
• Is low-dose opioid therapy appropriate in my case?
• Are there any clinical trials I might be eligible for?
• Should I be referred to a center with specialized RLS expertise?
• My RLS is affecting my mental health — should I be screened for depression or anxiety?

RLS is strongly associated with depression and anxiety, both as a consequence of chronic sleep deprivation and potentially through shared neurobiological mechanisms. Patients whose mood is affected should seek evaluation and treatment — addressing depression and anxiety can improve RLS management and quality of life. If an antidepressant is needed, bupropion is generally preferred over SSRIs/SNRIs because it is less likely to worsen RLS.

The invisibility of RLS compounds the emotional burden. Partners, family, and friends may not understand the severity because there is nothing to see. Sharing educational materials and involving family in medical appointments can help bridge this gap.

• Travel: Long flights and car rides are especially challenging. Request aisle seats on planes. Walk the aisle frequently. Take medication before travel. Consider compression stockings. For long drives, plan frequent stops.
• Work: If your job requires prolonged sitting, arrange for a standing desk option, frequent walk breaks, or fidget-friendly seating. Some patients find that under-desk exercise devices help.
• Social events: Movie theaters, concerts, and formal dinners can trigger symptoms. Sit in aisle seats where you can stand or walk easily. Let companions know why you may need to move.
• Medical procedures: Alert medical teams before surgeries, dental procedures, or any situation requiring prolonged immobility. Anti-nausea drugs commonly used in anesthesia (like metoclopramide) should be avoided; request ondansetron instead.

• Restless Legs Syndrome Foundation — rls.org. The primary patient advocacy organization. Provides educational materials, support groups, physician directories, and clinical trial listings. Helpline: 512-366-9109.
• American Academy of Sleep Medicine — aasm.org. Can help locate AASM-accredited sleep centers.
• Sleep Foundation — sleepfoundation.org. General sleep health information including RLS.
• Willis-Ekbom Disease Foundation (Europe) — European patient support organization.

• Horizant (gabapentin enacarbil) — The manufacturer (Arbor Pharmaceuticals) offers a patient assistance program and copay savings card. Visit horizant.com or call 1-866-516-4950.
• Generic pramipexole and ropinirole — Available at relatively low cost. Check GoodRx (goodrx.com) for pharmacy price comparisons.
• Pregabalin (Lyrica) — Now available as a generic, which has substantially reduced cost. Patient assistance programs may still be available through Pfizer.
• IV iron infusions — Often covered by insurance with prior authorization and documentation of failed oral iron therapy. If coverage is denied, appeal with supporting documentation from the sleep medicine specialist.
• NeedyMeds — needymeds.org, 800-503-6897. Database of prescription assistance programs.
• Patient Advocate Foundation — patientadvocate.org, 800-532-5274. Help with insurance navigation and copay relief.

Severe RLS can qualify as a disability under the Americans with Disabilities Act (ADA) if it substantially limits major life activities, including sleeping. Reasonable workplace accommodations may include flexible scheduling, standing desk options, permission for movement breaks, and adjusted work hours. A letter from the treating physician documenting the diagnosis, severity, and functional impact supports accommodation requests.

• Why brain iron is insufficient in RLS patients despite adequate peripheral iron levels is not fully understood. The mechanism of impaired brain iron uptake is an active area of research.
• Why RLS symptoms follow a circadian pattern is partially but not completely explained by dopaminergic circadian rhythms. Other factors likely contribute.
• Whether augmentation can be fully reversed or leaves lasting changes in dopaminergic circuits is uncertain. Most patients improve after dopamine agonist withdrawal, but some do not return to their pre-augmentation baseline.
• The optimal ferritin target for RLS management — whether 75, 100, or even higher — is still debated among experts.
• Whether cannabis products have genuine efficacy for RLS is unknown due to the absence of rigorous clinical trials.
• The role of glutamate, adenosine, and endogenous opioid systems in RLS pathophysiology, and whether targeting them will lead to new treatments, is still being worked out.
• How to reliably identify which patients will develop augmentation before prescribing dopamine agonists remains an unsolved clinical problem.

It is not uncertain that RLS is a real neurological disorder with biological underpinnings, not a psychological complaint. It is not uncertain that iron deficiency worsens RLS and that correcting it helps. It is not uncertain that augmentation is a major problem with chronic dopamine agonist therapy and that lower doses reduce the risk. It is not uncertain that alpha-2-delta ligands are effective for RLS without augmentation risk. It is not uncertain that many common medications can worsen RLS and that medication review should be part of every evaluation. It is not uncertain that RLS significantly impairs sleep, mood, and quality of life and deserves proper treatment. These are the foundations this guide rests on.

• Alpha-2-delta ligand — a class of medications (gabapentin, pregabalin, gabapentin enacarbil) that bind to calcium channels in the nervous system. Now recommended as first-line treatment for RLS.
• Augmentation — a treatment-induced worsening of RLS caused by chronic dopaminergic therapy. Symptoms start earlier, spread, and intensify. The most important complication of dopamine agonist treatment.
• Circadian rhythm — the body’s internal 24-hour clock that regulates sleep-wake cycles and many biological processes, including dopamine activity.
• Dopamine — a neurotransmitter involved in movement, motivation, and reward. Dopaminergic dysfunction in the brain is central to RLS.
• Dopamine agonist — a medication that stimulates dopamine receptors. Includes pramipexole, ropinirole, and rotigotine. Effective for RLS but carries risk of augmentation and impulse control disorders.
• Ferritin — a protein that stores iron. Serum ferritin levels reflect total body iron stores. The RLS-specific target is above 75 ng/mL.

• Gabapentin enacarbil (Horizant) — a sustained-release prodrug of gabapentin specifically FDA-approved for moderate-to-severe RLS.
• Glutamate — the brain’s main excitatory neurotransmitter. May be elevated in RLS, contributing to sensory symptoms.
• Impulse control disorder (ICD) — compulsive behaviors (gambling, shopping, eating, sexual behavior) that can occur as a side effect of dopamine agonist medications.
• IRLSSG — International Restless Legs Syndrome Study Group. The organization that establishes diagnostic criteria and publishes treatment guidelines.
• IRLS rating scale — the International RLS Rating Scale, a 10-question validated questionnaire scoring 0–40 to measure symptom severity.
• IV iron — intravenous iron infusion. Used when oral iron is insufficient, not tolerated, or rapid repletion is needed.
• MEIS1 — a gene identified as the strongest genetic risk factor for RLS. Involved in iron regulation and neuronal development.
• Periodic limb movements of sleep (PLMS) — repetitive, stereotyped leg movements during sleep, present in 80–90% of RLS patients.
• PLMI — Periodic Limb Movement Index. The number of periodic limb movements per hour of sleep, measured by polysomnography.
• Polysomnography — an overnight sleep study that records brain waves, eye movements, muscle activity, breathing, and leg movements.
• Pregabalin (Lyrica) — an alpha-2-delta ligand used off-label for RLS. Schedule V controlled substance.
• Primary RLS — RLS with no identifiable external cause, typically with genetic predisposition and family history.

• Refractory RLS — RLS that does not respond adequately to standard treatments including iron optimization, alpha-2-delta ligands, and dopamine agonists.
• Rotigotine (Neupro) — a dopamine agonist delivered as a transdermal patch, providing continuous 24-hour dopaminergic stimulation.
• Secondary RLS — RLS caused or worsened by another condition (iron deficiency, kidney disease, pregnancy, neuropathy, medications).
• Transferrin saturation (TSAT) — a blood test measuring the percentage of iron-binding sites on transferrin that are occupied by iron. Values below 20% suggest functional iron deficiency.
• Tyrosine hydroxylase — the rate-limiting enzyme in dopamine synthesis that requires iron as a cofactor.
• Willis-Ekbom Disease (WED) — the alternative name for Restless Legs Syndrome, honoring Thomas Willis (who described the condition in 1685) and Karl-Axel Ekbom (who systematically characterized it in 1945).

Guidelines:

• IRLSSG Diagnostic Criteria for RLS/WED (Allen RP et al., Sleep Medicine, 2014)
• AASM Clinical Practice Guideline for the Treatment of RLS (Winkelman JW et al., J Clin Sleep Med 2025;21(1) — published online Sept 2024; PMID 39324694)
• EURLSSG/IRLSSG Expert Consensus on Management of RLS Augmentation (Garcia-Borreguero D et al., Sleep Medicine, 2016;21:1–11)
• Mayo Clinic RLS Treatment Algorithm (Silber MH et al., Mayo Clinic Proceedings, 2021)
• IRLSSG Practice Guidelines for Long-term Treatment of RLS (Garcia-Borreguero D et al., Sleep Medicine Reviews, 2013)

Key studies and trials referenced in this guide:

• RLS Foundation (rls.org) — Primary patient advocacy organization. Helpline: 512-366-9109
• ClinicalTrials.gov (clinicaltrials.gov) — Official U.S. registry of clinical trials
• American Academy of Sleep Medicine (aasm.org) — Sleep center locator and patient education
• National Institute of Neurological Disorders and Stroke (ninds.nih.gov) — NIH RLS information page
• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
• Sleep Foundation (sleepfoundation.org) — General sleep health information